Research Leadership
The Kidney Cancer Research Consortium brings together some of the nation’s best researchers in clinical kidney cancer trials, enabling multi-site studies at a greatly reduced cost.
The collaborative nature of the Consortium also improves trial enrollment numbers and access to underserved populations of patients. The KCRC includes some of the highest volume renal cell carcinoma clinical trial sites in the country.
Clinical Trial Leadership
The Consortium sites are led by veteran researchers with over 100 years of combined experience. KCRC investigators are nationally and internationally renowned for their work and heralded as thought leaders around the globe.
What We Offer
KCRC researchers are leaders in clinical trial study design and kidney cancer treatment development. Collaboration between experienced researchers across multiple sites enables innovative study at a fraction of the cost of a traditional CRO.
Information for Patients
Patients with kidney cancer may benefit from participation in clinical trials at any point in their treatment. Read on for more information and to locate enrolling trials.
Research News
Kidney cancer research is a rapidly-advancing area of oncology. Read about the latest research coming from Consortium sites and others researching treatment for RCC.
The Kidney Cancer Research Consortium Members
The Consortium members have over 100 years of combined experience in kidney cancer clinical research. KCRC brings an unmatched commitment to and expertise to RCC trials.
Eric Jonasch, M.D.
Dr. Jonasch leads the Consortium. He is a professor in the Department of GU Medical Oncology, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center. Dr. Jonasch's research focuses on clear-cell RCC and VHL with an interest in replication stress and microenvironmental determinants of resistance to therapy.
Hans Hammers, M.D., Ph.D.
Dr. Hammers is a nationally and internationally recognized medical oncologist focusing primarily on kidney cancer. Dr. Hammers is an international thought leader in immunotherapy, a form of treatment that boosts the body’s own immune defenses to help fight cancer – and one that is changing the kidney cancer landscape.
Brian Rini, M.D.
Dr. Rini is an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development. He is an Ingram Professor of Medicine at Vanderbilt University in the deperatments of hematology and oncology, where he leads kidney cancer clinical research efforts, and also serves as the Chief of Clinical Trials.
Naomi Haas, M.D.
Dr. Haas is an international expert in the conduct and design of adjuvant clinical trials for kidney cancer, as well as a national expert in prostate and kidney cancer therapeutics. She is the director of the Prostate and Kidney Cancer Program at UPenn, as well as co-leader of the Cancer Therapeutics Program at Abramson Cancer Center.
Daniel George, M.D.
Dr. George oversees a large clinical research team at Duke focused on developing therapy and improving care and outcomes for patients with urologic cancers. His work involves both interventional trials with new and emerging therapies, as well as diagnostic tests and markers of cancer biology, response, and outcome.
David McDermott, M.D.
Dr. McDermott is a professor of medicine at Harvard, as well as the co-leader of the Kidney Cancer program at Dana-Farber/HCC. He focuses on identifying meaningful biomarkers for early detection and prognosis, underlying mechanisms of disease biology, and novel therapeutic targets for various kidney cancer populations.
Ulka Vaishampayan, M.D., Ph.D.
Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies.
The Latest Tweets from Consortium Investigators:
; The Academy of Kidney Cancer Investigators has updated their YouTube channel with a video of Jim Brugarolas discussing "Bench to Bedside and Back" @brian_rini #KidneyCancer
A total superstar. IM programs don't miss out!
Don't forget about the great AKCI YouTube page that houses our great lecture series!
Academy of Kidney Cancer Investigators AKCI
www.youtube.com
Celeste Simon joins us for the latest @Uromigos Legends Series podcast. She shares her story of perseverance through adversity, also highlighted in a recent essay:
https://spotifyanchor-web.app.link/e/ebOkU6FOGCb
hit us with a RT for your chance to win an authentic jersey worn by one of the guys at practice, courtesy of @Binary_Defense
full rules ➡️ https://brow.nz/uagg
Apply now for our Vanderbilt GU Oncology Research Fellowship starting July 2024. Great opportunity for honing clinical and research skills!
GU Oncology Fellowship - Nashville, Tennessee
The GU Oncology Fellowship at VUMC has been in existence since July 2021. This Fellowship lasts for one year.
careercenter.asco.org
Our team is assembled in DC and fueling up for KidneyCAN’s #AdvocacyDays!
Tomorrow, we meet with members of Congress to ask for robust funding for #kidneycancer research. THANK YOU to these patients and advocates who’ve come to tell their stories. 🧡💚
WATCH: @Daniel_J_George of @DukeCancer discusses managing adverse events associated with PARP inhibitor therapy in patients with prostate cancer. #pcsm | @DukeHealth
Événement ARTuR - Congrès scientifique
M-1 avant le 10e #Congrès de l'association #ARTuR ! Professionnels de la santé, nous vous donnons rendez-vous du 4 au 6 octobre au Domaine des Fontaines à Chantilly.
➡️ Retrouvez le programme et inscrivez-vous ici : https://colloquium.idloom.events/artur-2023
